Friday 29 April 2016
|09.45-10.00||Welcome and introductions, UK-CAB updates|
|10.00-10.45||HIV and menopause – Shema Tariq|
|10.45-11.15||Community engagement on BHIVA guidelines – Robert James|
|11.30-12.30||Personal experience: Trans*woman – Catalina Hermes|
|14.00-15.30||Community response to NHS PrEP reconsideration –NATAgeing conference feedback – Damian Kelly|
|15.40-16.15||Study discussion: Linkage to care following HIV diagnosis – Sarah Croxford, UCL
Conferences feedback: BHIVA -Dano Wheals, CROI
Stigma index – Alastair Hudson,
London Combined Audit &Outcomes and Drug & Treatment Sub Group – Virginia Cucchi
|16.45||AOB, meeting close|
Presentations from this meeting
The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.
The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.
We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.
For a list of companies that support the UK-CAB please see the “about us” page.